MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Use of Lead Candidate MYMD-1 for Treating Fibrosis and Asthma
August 24 2021 - 10:17AM
Business Wire
Patent protects methods of administering MYMD-1
for treating disorders associated with chronic inflammation, with a
focus on fibrosis and asthma
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the
Company”), a clinical stage pharmaceutical company committed to
extending healthy lifespan by focusing on developing two
therapeutic platforms, today announced that the United States
Patent and Trademark Office (USPTO) has issued U.S. Patent No.
11,096,933 titled “Method of Treating Disorders Associated with
Chronic Inflammation.”
The ’933 patent becomes the thirteenth patent protecting the
Company’s lead candidate MYMD-1, a synthetic small molecule being
developed to treat autoimmune and age-related diseases, including
extending human lifespan, and which has been shown effective in
regulating the immune system in preclinical studies.
"Nearly 100,000 people in the United States have idiopathic
pulmonary fibrosis (IPF), and although cases continue to climb,
there is still a significant unmet need in treatment options for
this chronic disease,” said Chris Chapman, M.D., President,
Director and Chief Medical Officer. “This latest patent underscores
MYMD-1’s potential to inhibit inflammation, which is linked to
myriad diseases including IPF.”
A study conducted by Eurofins Discovery Phenotypic Center of
Excellence identified the potential of MYMD-1 to limit the fibrotic
biology associated with IPF. Hallmark activities of MYMD-1 included
inhibition of transforming growth factor-beta (TGF-beta), a driver
for fibrosis, and of tumor necrosis factor (TNF), associated with
inflammation. This dual pattern of anti-fibrotic and
anti-inflammatory activities are consistent with the potential for
MYMD-1 to be developed as a therapeutic candidate for
fibrosis-related diseases.
Fibrotic disorders are implicated in nearly 45% of all deaths in
the developed world, and may involve multiple physiological systems
including the skin, liver, kidney, heart and lungs. In particular,
IPF has an insidious, relentless and chronic course, with a median
survival of two to five years. Thus, there is a great need to
develop new and effective therapeutics for treating patients.
About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals,
Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company
committed to extending healthy lifespan, is focused on developing
two novel therapeutic platforms that treat the causes of disease
and decline rather than only addressing the symptoms. MYMD-1 is a
drug platform based on a clinical stage small molecule that
regulates the immunometabolic system to control TNF-α, a driver of
chronic inflammation, and other pro-inflammatory cell signaling
cytokines. MYMD-1 is being developed to treat aging and longevity,
autoimmune diseases, and COVID-19- associated depression and
cytokine elevation. The Company’s second drug platform, Supera-CBD,
is being developed to treat chronic pain, addiction and epilepsy.
Based on a novel synthetic derivative of cannabidiol (CBD),
Supera-CBD is being developed to address the rapidly growing CBD
market, which includes both FDA approved drugs and CBD products not
currently regulated as drugs. For more information, visit
www.mymd.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release may contain forward-looking statements. These
forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause actual results,
performance or achievements to be materially different from any
expected future results, performance, or achievements.
Forward-looking statements speak only as of the date they are made
and none of MyMD nor its affiliates assume any duty to update
forward-looking statements. Words such as "anticipate," "believe,"
"could," "estimate," "expect," "may," "plan," "will," "would'' and
other similar expressions are intended to identify these
forward-looking statements. Important factors that could cause
actual results to differ materially from those indicated by such
forward-looking statements include, without limitation: the timing
of, and MyMD’s ability to, obtain and maintain regulatory approvals
for clinical trials of MyMD’s pharmaceutical candidates; the timing
and results of MyMD’s planned clinical trials for its
pharmaceutical candidates; the amount of funds MyMD requires for
its pharmaceutical candidates; increased levels of competition;
changes in political, economic or regulatory conditions generally
and in the markets in which MyMD operates; MyMD’s ability to retain
and attract senior management and other key employees; MyMD’s
ability to quickly and effectively respond to new technological
developments; MyMD’s ability to protect its trade secrets or other
proprietary rights, operate without infringing upon the proprietary
rights of others and prevent others from infringing on MyMD’s
proprietary rights; and the impact of the ongoing COVID-19 pandemic
on MyMD’s results of operations, business plan and the global
economy. A discussion of these and other factors with respect to
MyMD is set forth in the Quarterly Report on Form 10-Q for the
quarterly period ended June 30, 2021, filed by MyMD on August 16,
2021. Forward-looking statements speak only as of the date they are
made and MyMD disclaims any intention or obligation to revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210824005213/en/
Investor Contact: Robert Schatz (646) 421-9523
rschatz@mymd.com www.mymd.com
MyMD Pharmaceuticals (NASDAQ:MYMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MyMD Pharmaceuticals (NASDAQ:MYMD)
Historical Stock Chart
From Apr 2023 to Apr 2024